Chronic wounds represent a significant burden on patients and healthcare systems, often prolonged due to conditions like diabetes mellitus, which impairs blood flow and hinders natural healing. These wounds, typically requiring frequent monitoring and dressing changes – sometimes for up to a year – contribute substantially to economic strain. Treatment is typically managed by a multidisciplinary team.
Researchers at Empa are developing an innovative material utilizing visible light to control **drug delivery** for chronic wound treatment. The material incorporates silica nanoparticles loaded with chlorhexidine, a wound disinfectant, coated with polymer shells containing molecular photoswitches. Exposure to visible LED light causes the polymer to swell, releasing the chlorhexidine. When the light is removed, the polymer contracts, restoring its watertight form. This controlled release minimizes the risk of bacterial resistance and reduces potential side effects.
This system enables personalized wound treatment by allowing precise control over the timing and dosage of the active ingredient. The potential exists to combine this technology with a wound sensor, continuously monitoring bacterial levels and adjusting the light exposure accordingly. This would enable targeted treatment based on the specific infection present. The team is currently adapting the system for clinical use, collaborating with hospitals and seeking doctoral students to further develop the technology. Clinical trials will be necessary before approval as a medical device, but successful implementation could reduce hospital visits and ease the burden on the healthcare system.
Ultimately, this light-controlled drug delivery system aims to shift from standardized wound care to a more tailored approach, potentially offering a significant benefit to individuals with diabetic foot syndrome and reducing the overall impact of chronic wounds on healthcare resources.